Global Autism Spectrum Disorder Diagnostics Market Report

The global Autism Spectrum Disorder Diagnostics market is forecasted to grow at a noteworthy CAGR of 4.86% between 2025 and 2033. By 2033, market size is expected to surge to USD 56.95 Billion, a substantial rise from the USD 37.15 Billion recorded in 2024.

Autism Spectrum Disorder Diagnostics Market Size and Forecast 2025 to 2033

The Autism Spectrum Disorder Diagnostics market is propelled by a confluence of factors that underscore the escalating need for early and accurate diagnosis. A primary driver is the demonstrable increase in the global prevalence of Autism Spectrum Disorder. This heightened prevalence, as evidenced by various public health organizations, necessitates more robust and accessible diagnostic tools and services. Alongside this, advancements in diagnostic technologies, including the development of more sophisticated screening instruments and biomarker research, are expanding the capabilities of the market. Furthermore, growing awareness among parents, educators, and healthcare professionals about the early signs of Autism Spectrum Disorder is leading to earlier detection and intervention. This increased understanding is crucial in driving individuals towards diagnostic pathways. Opportunities within this market are substantial, stemming from the unmet need for earlier and more definitive diagnostic solutions, particularly in underserved regions. The integration of artificial intelligence and machine learning in diagnostic processes also presents a significant avenue for growth, promising enhanced accuracy and efficiency. Additionally, the expansion of telemedicine and remote diagnostic services offers a novel pathway to reach a broader population, overcoming geographical barriers and improving access to specialized diagnostic expertise.

Market Dynamics

Autism Spectrum Disorder Diagnostics Market Drivers

• Rising Global Prevalence of Autism Spectrum Disorder: The increasing incidence of Autism Spectrum Disorder globally is a significant driver for the diagnostics market. Data from the Centers for Disease Control and Prevention (CDC) in the United States indicates a consistent rise in Autism Spectrum Disorder diagnoses. For instance, the CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network reported that about 1 in 36 children were identified with Autism Spectrum Disorder. This upward trend highlights a growing population requiring diagnostic evaluation, consequently stimulating demand for diagnostic tools, services, and qualified professionals. The broader understanding of Autism Spectrum Disorder and improved screening practices also contribute to the recognition of more cases, further fueling this market. This demographic shift necessitates a robust and accessible diagnostic infrastructure to identify individuals across various age groups and ensure timely intervention.
• Growing Awareness and Early Intervention Initiatives: Enhanced public awareness and proactive early intervention programs are critical drivers in the Autism Spectrum Disorder diagnostics market. Educational campaigns by organizations such as the National Institute of Mental Health (NIMH) emphasize the importance of recognizing early developmental milestones and atypical behaviors associated with Autism Spectrum Disorder. This increased understanding among parents, caregivers, and healthcare providers leads to earlier identification of potential cases. For instance, the National Institutes of Health (NIH) promotes early screening as a crucial step for improved outcomes. The emphasis on early diagnosis allows for the implementation of therapeutic interventions at a developmental stage where they can be most effective, thereby driving the demand for precise and efficient diagnostic assessments.
• Technological Advancements in Diagnostic Tools: The continuous evolution of diagnostic technologies significantly propels the Autism Spectrum Disorder diagnostics market. Innovations in medical imaging, genetic testing, and neurophysiological assessments are enhancing the accuracy and objectivity of diagnostic procedures. For instance, the National Human Genome Research Institute (NHGRI) highlights the role of genetic research in identifying markers associated with Autism Spectrum Disorder, leading to more targeted diagnostic approaches. The development of sophisticated behavioral assessment tools, eye-tracking technology, and digital platforms for symptom analysis also contributes to this advancement. These technological innovations not only streamline the diagnostic process but also offer more nuanced insights into the diverse presentations of Autism Spectrum Disorder, thereby increasing the reliability of diagnoses.
• Supportive Government Initiatives and Funding: Government support and dedicated funding for Autism Spectrum Disorder research and diagnostic services are crucial drivers. Agencies like the National Institute of Child Health and Human Development (NICHD) within the National Institutes of Health (NIH) allocate significant resources towards understanding Autism Spectrum Disorder, developing diagnostic criteria, and improving access to services. These initiatives often include funding for research into novel diagnostic biomarkers and the implementation of screening programs in healthcare settings. Such governmental backing not only accelerates the development and adoption of new diagnostic techniques but also ensures a wider reach for diagnostic services, ultimately stimulating market growth by reducing financial barriers for individuals seeking assessment.

Autism Spectrum Disorder Diagnostics Market Opportunities

• Integration of Artificial Intelligence and Machine Learning in Diagnosis: The application of artificial intelligence (AI) and machine learning (ML) algorithms presents a substantial opportunity within the Autism Spectrum Disorder diagnostics market. These technologies can analyze complex datasets, including behavioral observations, genetic information, and neuroimaging data, with greater efficiency and precision than traditional methods. For instance, research supported by the National Institutes of Health (NIH) has explored the use of AI to identify subtle patterns in speech or eye movements that may indicate Autism Spectrum Disorder, potentially leading to earlier and more objective diagnoses. The ability of AI and ML to learn from vast amounts of data can also improve the accuracy of diagnostic predictions, reduce diagnostic delays, and assist clinicians in making more informed decisions, thereby expanding the scope and efficacy of diagnostic services.
• Expansion of Telemedicine and Remote Diagnostic Solutions: The increasing adoption of telemedicine and remote healthcare delivery models offers a significant opportunity for expanding access to Autism Spectrum Disorder diagnostics. Telemedicine allows for assessments to be conducted remotely, overcoming geographical barriers and improving access for individuals in underserved or rural areas. The Health Resources and Services Administration (HRSA) has emphasized the potential of telehealth to improve access to specialty care. This approach can facilitate initial screenings, follow-up consultations, and even some aspects of comprehensive diagnostic evaluations, particularly for behavioral observations and parental interviews. The convenience and reduced logistical burden associated with remote diagnostics can lead to a greater uptake of diagnostic services, thereby broadening the market's reach and impact.
• Development of Biomarker-Based Diagnostic Tools: The discovery and validation of novel biomarkers for Autism Spectrum Disorder represent a critical market opportunity. Biomarkers, which can include genetic, proteomic, or neuroimaging indicators, offer the potential for more objective and early diagnostic methods, even before behavioral symptoms become clearly evident. The National Institute of Mental Health (NIMH) actively funds research into identifying reliable biomarkers for Autism Spectrum Disorder, recognizing their potential to transform diagnostic practices. The availability of such tools could significantly reduce the subjectivity often associated with current behavioral assessments, leading to more accurate and timely diagnoses. This area holds immense promise for personalized diagnostics and early intervention strategies, driving investment and innovation within the market.
• Increased Investment in Early Childhood Screening Programs: A greater emphasis on and investment in universal early childhood screening programs for developmental delays, including Autism Spectrum Disorder, presents a significant market opportunity. The Centers for Disease Control and Prevention (CDC) advocates for early screening to ensure timely intervention. Implementing widespread screening initiatives in pediatric clinics, schools, and community health centers would lead to the identification of a larger cohort of children at risk for Autism Spectrum Disorder. This proactive approach would subsequently increase the demand for confirmatory diagnostic evaluations. Such programs, supported by public health policies and funding, could systematically integrate Autism Spectrum Disorder screening into routine developmental check-ups, thereby creating a sustained and expanding demand for diagnostic tools and professional services.

Autism Spectrum Disorder Diagnostics Market Restrain & Challenges

• Lack of Standardized Diagnostic Criteria and Training: A significant challenge in the Autism Spectrum Disorder diagnostics market is the lack of universally standardized diagnostic criteria and consistent training for clinicians. While diagnostic manuals like the DSM-5 provide guidelines, their interpretation and application can vary among practitioners and regions. The National Academies of Sciences, Engineering, and Medicine have highlighted the need for more consistent approaches to diagnosis. This variability can lead to inconsistent diagnoses, diagnostic delays, or even misdiagnoses, impacting patient care and market efficiency. The absence of uniform training programs for healthcare professionals, particularly in recognizing the diverse presentations of Autism Spectrum Disorder, further exacerbates this issue, hindering the seamless adoption and utilization of advanced diagnostic tools.
• High Cost of Comprehensive Diagnostic Assessments: The substantial cost associated with comprehensive Autism Spectrum Disorder diagnostic assessments poses a significant restraint for market growth. These assessments often involve a multidisciplinary team, specialized tools, and multiple sessions, making them expensive. The American Academy of Pediatrics acknowledges the resource intensity of these evaluations. For many families, particularly those without robust insurance coverage or in lower-income settings, the financial burden can be prohibitive, leading to delayed or forgone diagnoses. This cost barrier limits access to essential diagnostic services, especially in regions with developing healthcare infrastructures, thereby restricting the overall market penetration and equitable distribution of diagnostic solutions.
• Limited Availability of Skilled Diagnostic Professionals: A critical challenge facing the Autism Spectrum Disorder diagnostics market is the scarcity of highly trained and experienced professionals capable of conducting comprehensive assessments. These specialists, including developmental pediatricians, child psychologists, and speech-language pathologists, require extensive training in Autism Spectrum Disorder differential diagnosis. The U.S. Department of Health and Human Services has noted shortages in various healthcare specialties. This shortage is particularly pronounced in rural and underserved areas, leading to long waiting lists for evaluations and significant diagnostic delays. The limited workforce directly impacts the capacity to meet the growing demand for diagnoses, creating bottlenecks in the diagnostic pathway and hindering the overall expansion of the market.
• Stigma Associated with Autism Spectrum Disorder Diagnosis: The societal stigma often associated with an Autism Spectrum Disorder diagnosis presents a considerable challenge, influencing parents' willingness to seek evaluation for their children. Despite increasing awareness, misconceptions and negative perceptions surrounding Autism Spectrum Disorder persist. The National Alliance on Mental Illness (NAMI) has addressed the broader issue of mental health stigma. This stigma can lead to denial, delay in seeking professional help, or even reluctance to accept a diagnosis once given. Such reluctance directly impacts the uptake of diagnostic services, as families may fear social judgment or implications for their child's future. Overcoming this deeply rooted societal barrier requires ongoing public education and destigmatization efforts, which are crucial for the full potential of the diagnostic market to be realized.

Current Trends in the Autism Spectrum Disorder Diagnostics Market

• Rise of Digital Biomarkers and AI-Powered Screening Tools: A prominent trend in the Autism Spectrum Disorder diagnostics market is the emergence of digital biomarkers and the increasing integration of artificial intelligence (AI) in screening tools. Researchers, often supported by institutions like the National Institute of Mental Health (NIMH), are exploring digital markers derived from passive data collection, such as eye-tracking patterns, vocalizations, or movement analysis captured via smart devices and cameras. AI algorithms then analyze these vast datasets to identify subtle deviations indicative of Autism Spectrum Disorder, potentially enabling earlier and more objective screening. This trend holds the promise of transforming current labor-intensive assessments into scalable and less invasive methods, thereby improving accessibility and potentially reducing diagnostic age.
• Focus on Early Diagnosis and Pre-Symptomatic Screening: There is a growing emphasis on achieving earlier diagnosis, including pre-symptomatic screening, to facilitate timely intervention. This trend is driven by mounting evidence, often highlighted by organizations such as the Centers for Disease Control and Prevention (CDC), demonstrating the significant benefits of early intervention for developmental outcomes in individuals with Autism Spectrum Disorder. Research is increasingly focusing on identifying risk factors and subtle indicators in infants and toddlers, well before the typical age of diagnosis. This includes genetic screening and neuroimaging studies aiming to detect neural atypicalities. The shift towards proactive early detection aims to reduce diagnostic delays and allow for the implementation of therapeutic strategies during critical developmental windows, thereby shaping future diagnostic product development.
• Development of Non-Invasive Diagnostic Approaches: A significant trend in the Autism Spectrum Disorder diagnostics market is the development of non-invasive diagnostic methodologies. Traditional assessments often rely on subjective behavioral observations, which can be resource-intensive and require specialized expertise. Current research, supported by institutions like the National Institutes of Health (NIH), is exploring less intrusive methods, such as analyzing speech patterns, facial expressions, or even gut microbiome composition as potential indicators. The aim is to create diagnostic tools that are less stressful for individuals, particularly children, and easier to administer in diverse settings. This trend represents a move towards more accessible, comfortable, and potentially scalable diagnostic solutions that can integrate seamlessly into routine healthcare check-ups.
• Integration of Multi-Omics Data for Comprehensive Diagnosis: The integration of multi-omics data, encompassing genomics, proteomics, metabolomics, and epigenomics, is a burgeoning trend in the Autism Spectrum Disorder diagnostics market. This approach aims to provide a more holistic understanding of the biological underpinnings of Autism Spectrum Disorder, moving beyond purely behavioral assessments. The National Human Genome Research Institute (NHGRI) is actively involved in advancing genomic research, which plays a crucial role in this trend. By combining insights from various biological layers, researchers seek to identify distinct Autism Spectrum Disorder subtypes, predict individual responses to interventions, and develop more personalized diagnostic and therapeutic strategies. This data-driven approach promises to enhance the precision and predictive power of diagnostic assessments, leading to more targeted and effective interventions.

Segmentation Insights

Autism Spectrum Disorder Diagnostics market Analysis, By Disease

By disease type, the market includes Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder (PDD), and Other.

• The largest segment within the Autism Spectrum Disorder diagnostics market by disease is Autistic Disorder. This prominence stems from its historical recognition as the quintessential form of Autism Spectrum Disorder, encompassing the classic presentation of social communication deficits, repetitive behaviors, and restricted interests. Clinically, Autistic Disorder represents the more severe end of the Autism Spectrum Disorder spectrum, leading to more pronounced and readily identifiable symptoms that often necessitate formal diagnostic evaluation at an earlier age. The well-established diagnostic criteria and the high prevalence of individuals meeting these criteria contribute significantly to its dominant position. Healthcare systems and diagnostic centers are primarily equipped to identify and assess these typical presentations, further solidifying its leading role in the market.
• The fastest-growing segment within the Autism Spectrum Disorder diagnostics market by disease is Pervasive Developmental Disorder (PDD). This segment, particularly PDD-NOS (Not Otherwise Specified), previously served as a broad category for individuals who exhibited some but not all criteria for Autistic Disorder or Asperger Syndrome. The inclusion of PDD within the market segment reflects the growing recognition of a wider phenotypic expression of Autism Spectrum Disorder and the increasing diagnostic capture of individuals who might not fit neatly into the more classic definitions. As diagnostic understanding evolves and awareness of the spectrum's breadth increases, more individuals are being identified within this broader category, driving its accelerated growth. This growth signifies a move towards more inclusive and nuanced diagnostic practices.

Autism Spectrum Disorder Diagnostics market Analysis, By Service

By Service, the market is categorized into Behavioural Approaches, Early Intervention, Medication, Other.

• The largest segment within the Autism Spectrum Disorder diagnostics market by service is Behavioural Approaches. This dominance is attributed to the foundational role of behavioral assessments in the diagnostic process. Comprehensive diagnostic evaluations for Autism Spectrum Disorder heavily rely on observing and analyzing an individual's communication, social interaction, and repetitive behaviors. Tools such as the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R) are central to this approach, providing clinicians with structured frameworks for assessment. Furthermore, behavioral approaches are often the first line of diagnostic inquiry when concerns about Autism Spectrum Disorder arise, making them an indispensable component of the diagnostic pathway. The established efficacy and widespread acceptance of these methods contribute to their leading position in the market.
• The fastest-growing segment within the Autism Spectrum Disorder diagnostics market by service is Early Intervention. This accelerated growth is driven by the increasing understanding and compelling evidence, often highlighted by organizations like the Centers for Disease Control and Prevention (CDC), demonstrating the profound benefits of early therapeutic intervention for individuals with Autism Spectrum Disorder. There is a growing societal and clinical emphasis on identifying Autism Spectrum Disorder as early as possible to initiate targeted therapies during critical developmental windows. This paradigm shift has created a significant demand for diagnostic services that can facilitate early identification, directly feeding into early intervention programs. The focus on maximizing developmental outcomes through timely support is a primary factor fueling the rapid expansion of this service segment.

Autism Spectrum Disorder Diagnostics market Analysis, By Location

By Location, the market is categorized into Hospitals, Education Counsellor Center, Others.

• The largest segment within the Autism Spectrum Disorder diagnostics market by location is Hospitals. This is primarily due to hospitals often serving as central hubs for specialized medical services, including developmental pediatric departments, neurology clinics, and child psychiatry units, which are crucial for comprehensive Autism Spectrum Disorder evaluations. Hospitals typically house multidisciplinary teams of experts, such as developmental pediatricians, child psychologists, neurologists, and geneticists, who are essential for complex diagnostic assessments. Furthermore, hospitals often have access to advanced diagnostic technologies, including neuroimaging and genetic testing facilities, which are increasingly integrated into the diagnostic process. Their comprehensive infrastructure and ability to manage complex cases make them the primary destination for definitive Autism Spectrum Disorder diagnoses.
• The fastest-growing segment within the Autism Spectrum Disorder diagnostics market by location is Education Counsellor Centers. This accelerated growth is driven by the increasing awareness of Autism Spectrum Disorder within the educational system and the crucial role schools play in identifying children who may require assessment. Education counselor centers often serve as the first point of contact for parents and teachers who observe developmental differences or behavioral challenges in children. As educational institutions become more attuned to the signs of Autism Spectrum Disorder, their counselors are increasingly pivotal in initiating the diagnostic pathway by referring children for further evaluation. This rising integration of diagnostic preliminary steps within educational settings, coupled with increased focus on early identification in schools, is fueling the rapid expansion of this segment.

Autism Spectrum Disorder Diagnostics Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the Autism Spectrum Disorder Diagnostics market is North America. This dominance is attributable to several factors, including a highly developed healthcare infrastructure, significant awareness regarding Autism Spectrum Disorder, and substantial research and development investments in diagnostic technologies. Countries like the United States have well-established diagnostic protocols and a high prevalence of reported Autism Spectrum Disorder cases, driving demand for comprehensive assessments. Furthermore, favorable reimbursement policies and the presence of numerous key market players and research institutions contribute to the region's leading position. The emphasis on early screening and intervention, coupled with robust public health initiatives, further solidifies North America's significant market share in Autism Spectrum Disorder diagnostics.
• The fastest-growing region in the Autism Spectrum Disorder Diagnostics market is Asia-Pacific. This rapid expansion is primarily driven by increasing awareness of Autism Spectrum Disorder, improving healthcare infrastructure, and a growing emphasis on early diagnosis and intervention across various countries in the region. Emerging economies within Asia-Pacific are witnessing significant investments in healthcare, leading to improved access to diagnostic services. Additionally, rising disposable incomes, coupled with supportive government initiatives aimed at addressing developmental disorders, are contributing to the increased demand for Autism Spectrum Disorder diagnostics. The vast population base and the relatively lower diagnostic rates historically in some parts of the region present substantial untapped potential, fueling this accelerated market growth.

Autism Spectrum Disorder Diagnostics Market Competitive Overview

The competitive landscape of the Autism Spectrum Disorder Diagnostics market is characterized by a blend of established healthcare companies and innovative biotechnology and medtech firms. These entities are actively engaged in research and development to introduce advanced diagnostic tools and platforms, ranging from genetic tests and neuroimaging solutions to behavioral assessment software. A key focus for many players is the enhancement of diagnostic accuracy and the reduction of the age of diagnosis, aiming to facilitate earlier intervention. The market is also seeing increasing collaboration between technology developers and clinical institutions to validate and integrate new diagnostic methodologies into standard practice. Companies are striving to offer comprehensive solutions that address the multifaceted nature of Autism Spectrum Disorder diagnosis, including pre-symptomatic screening and differential diagnosis from other neurodevelopmental conditions. This dynamic environment fosters continuous innovation, driven by the persistent need for more efficient and precise diagnostic pathways.

Leading Market Players in the Autism Spectrum Disorder Diagnostics Market

• Jazz Pharmaceuticals: Jazz Pharmaceuticals is a prominent player in the Autism Spectrum Disorder diagnostics market, primarily through its strategic involvement in therapies that address co-occurring conditions or specific symptoms associated with Autism Spectrum Disorder. While not directly a diagnostics company, their focus on neuroscience and psychiatric disorders positions them to potentially impact the broader diagnostic ecosystem through research and development. Their pipeline often includes compounds that could necessitate refined diagnostic approaches for patient stratification or treatment monitoring. Their engagement reflects the growing understanding that effective management of Autism Spectrum Disorder involves addressing its diverse symptomatology, thereby influencing the need for comprehensive diagnostic profiles.
• Cognoa Inc: Cognoa Inc. is a leading innovator in the Autism Spectrum Disorder diagnostics market, recognized for its development of AI-powered diagnostic solutions. The company's focus is on creating software-as-a-medical-device (SaMD) platforms that leverage artificial intelligence and machine learning to aid in the early detection and diagnosis of Autism Spectrum Disorder. Their approach aims to provide objective and scalable diagnostic tools that can be utilized in various clinical settings. By analyzing data from videos and questionnaires, Cognoa seeks to streamline the diagnostic process, reduce diagnostic delays, and improve access to timely evaluations, ultimately aiming to revolutionize how Autism Spectrum Disorder is identified.
• Johnson & Johnson: Johnson & Johnson is a significant entity in the broader healthcare landscape, with its involvement in the Autism Spectrum Disorder diagnostics market stemming from its extensive research and development capabilities in neuroscience and pharmaceuticals. While their primary focus might be on therapeutic interventions for Autism Spectrum Disorder and related conditions, their comprehensive approach to healthcare often includes supporting advancements in diagnostics. Their investments in understanding neurodevelopmental disorders contribute to the scientific knowledge base that underpins diagnostic innovation. Through their pharmaceutical segment and broader healthcare initiatives, Johnson & Johnson plays a role in the ecosystem that drives improvements in diagnostic pathways and tools for Autism Spectrum Disorder.

Top Strategies Followed by Players

• Strategic Collaborations and Partnerships: A key strategy adopted by players in the Autism Spectrum Disorder diagnostics market involves forging strategic collaborations and partnerships with academic institutions, research organizations, and other healthcare entities. These alliances often aim to leverage diverse expertise and resources for accelerated research and development of novel diagnostic tools and platforms. For instance, data from the National Institutes of Health (NIH) frequently highlights research collaborations between pharmaceutical companies and university labs, leading to breakthroughs in genetic biomarkers for Autism Spectrum Disorder. Such partnerships facilitate the pooling of scientific knowledge, clinical trial capabilities, and market access, enabling companies to bring innovative diagnostic solutions to market more efficiently and with greater validation.
• Investment in Research and Development for Novel Biomarkers: A significant strategy employed by market players is substantial investment in research and development (R&D) focused on identifying and validating novel biomarkers for Autism Spectrum Disorder. This includes exploring genetic, proteomic, metabolomic, and neuroimaging markers that can provide more objective and early diagnostic indicators. For instance, the National Institute of Mental Health (NIMH) reports ongoing funding for studies investigating blood-based biomarkers for Autism Spectrum Disorder. This proactive R&D approach is driven by the desire to move beyond purely behavioral assessments and achieve more precise, reproducible, and earlier diagnoses, thereby creating a competitive advantage through differentiated diagnostic products and services.
• Expansion into Emerging Markets and Underserved Regions: Companies in the Autism Spectrum Disorder diagnostics market are increasingly focusing on expanding their presence into emerging markets and underserved geographical regions. This strategy is driven by the recognition of significant unmet diagnostic needs and the potential for substantial market growth in these areas, where diagnostic infrastructure may be less developed. The World Health Organization (WHO) has highlighted the global disparity in access to healthcare services, including those for neurodevelopmental disorders. By developing scalable and affordable diagnostic solutions and establishing local partnerships, companies aim to increase accessibility to Autism Spectrum Disorder diagnostics in these regions, thereby capturing new market share and contributing to global health equity.

List of Companies Profiled in the Report are:

• Jazz Pharmaceuticals
• Axial therapeutics
• dfusion inc.
• Cognoa Inc
• Johnson & Johnson
• Novartis AG
• Abbvie Inc
• Curemark LLC
• EarliTec Diagnostics Inc
• Bristol Myers Squibb Co.

Global Autism Spectrum Disorder Diagnostics Market Report: Scope

List of Segments Covered

This section of the Autism Spectrum Disorder Diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease

• Autistic Disorder
• Asperger Syndrome
• Pervasive Development Disorder (PDD)
• Other

By Service

• Behavioural Approaches
• Early Intervention
• Medication
• Other

By Location

• Hospitals
• Education Counsellor Center
• Others